Top pharma cos’ R&D returns continue to slide: Deloitte

The collective R&D returns for this cohort have declined markedly, from 10.1% in 2010 to just 4.2% in 2015

0a44a71

(Photo Courtesy: www.blogs.scientificamerican.com)

While the Research and Development (R&D) divisions of 12 leading pharmaceutical companies have progressed 306 assets into late-stage pipelines since 2010, with projected lifetime returns of over $1.41 trillion, these returns are continuing to decline in percentage terms, according to a study produced by Deloitte in collaboration with research and consulting firm GlobalData.

This study, published by the Deloitte Centre for Health Solutions, states that the original cohort has launched 186 products since 2010, with a projected lifetime value of just under $1.26 trillion.

However, the collective R&D returns for this cohort have declined markedly, from 10.1% in 2010 to just 4.2% in 2015, while the average cost of asset development has risen by a third.

The study focuses on a longer-term view of R&D returns, as this reduces the volatility of static measures, which can be skewed by particularly high or low revenue expectations.

As assets can take approximately 15 years to progress from discovery to launch, and revenue forecasts can change substantially as they progress through late-stage development, a longer-term view provides a more robust analysis of an organization's likely R&D returns.

 

Previous 1 3 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X